Pharmaceuticals Acquisitions in Oregon

Agno Pharma has acquired Actylis Eugene, the legacy Cascade Chemistry manufacturing asset in Eugene, Oregon, expanding Agno's U.S. cGMP API development and manufacturing footprint. The site includes a 16,000 sq. ft. R&D lab and a newly constructed 30,000 sq. ft. GMP manufacturing facility, enhancing Agno's capabilities to support biotech and pharmaceutical clients from early-phase through commercial API production.

Bain Capital Life Sciences led a strategic growth investment of more than $200 million in Serán Bioscience, with existing investor Vivo Capital remaining a key shareholder. The capital will fund a new commercial-scale manufacturing campus in Bend, Oregon, expanding Serán's development, analytical and commercial manufacturing capabilities across multiple drug delivery modalities.

Aceto, a global provider of specialty materials for life sciences and advanced technology end markets, acquired Eugene, Oregon-based Cascade Chemistry, a CDMO specializing in active pharmaceutical ingredients (APIs) and advanced intermediates. The acquisition strengthens Aceto's U.S. cGMP custom manufacturing capabilities and expands North American API manufacturing capacity; Cascade Chemistry recently announced a facility expansion that will triple its clinical-stage API capacity.